Aldoss I et al. Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Topline efficacy and safety results from the pivotal augment-101 phase 2 study. ASH 2023;Abstract LBA-5.
Atluri H et al. Phase Ib/2 study of oral decitabine/cedazuridine (ASTX727) and venetoclax in combination with the targeted mutant IDH1 inhibitor ivosidenib or the targeted mutant IDH2 inhibitor enasidenib: 2023 Update. ASH 2023;Abstract 968.
Bajel A et al. First-in-human study of the KD123 KN cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia: Updated safety, efficacy, pharmacokinetics and pharmacodynamics. ASH 2023;Abstract 3474.
Bazinet A et al. A phase 2 study of the fully oral combination of ASTX727 (decitabine/cedazuridine) plus venetoclax for older and/or unfit patients with acute myeloid leukemia. ASH 2023;Abstract 833.
Daver NG et al. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: A phase 1/2 study. Lancet Oncol 2024;25(3):388-99. Abstract
de Botton S et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv 2023;7(13):3117-27. Abstract
Erba HP et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10388):1571-83. Abstract
Fathi A et al. Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with R/R NPM1-mutated AML. EHA 2023;Abstract LB2713.
Garcia-Manero G et al. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: A phase 1, dose-finding and expansion study. Lancet Haematol 2023;10(4):e272-83. Abstract
Garciaz S et al. Acute myeloid leukemia patients who stopped venetoclax or/and azacytidine for other reasons than progression have a prolonged treatment free remission and overall survival. A Filo study. ASH 2023;Abstract 161.
Guolo F et al. Optimal duration of CPX-351 treatment and best timing for consolidation with allogeneic stem cell transplantation: Evidence from a large real-world Italian study. ASH 2023;Abstract 731.
Issa GC et al. Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE). ASH 2023;Abstract 58.
Jabbour E et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. ASH 2023;Abstract 57.
Kadia T et al. A phase 2 study of the fully oral combination of ASTX727 (decitabine/cedazuridine) plus venetoclax for older and/or unfit patients with acute myeloid leukemia. ASH 2023;Abstract 833.
Levis MJ et al. BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023;Abstract LB2711.
Levis MJ et al. Post-hoc analysis of measurable residual disease from BMT-CTN 1506/morpho: FLT3-ITD variant allele frequency and survival are highly correlated. ASH 2023;Abstract 973.
Montesinos P et al. Preliminary results of QUIWI: A double blinded, randomized clinical trial comparing standard chemotherapy plus quizartinib versus placebo in adult patients with newly diagnosed FLT3-ITD wild-type AML. EHA 2023;Abstract S130.
Pabst T et al. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): Part one of a randomised, phase 2, dose optimisation study. Lancet Haematol 2023;10(11):e902-12. Abstract
Perl A et al. Quantum-first trial: FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)–specific measurable residual disease (MRD) clearance assessed through induction (IND) and consolidation (CONS) is associated with improved overall survival (OS) in newly diagnosed (nd) FLT3-ITD+ AML patients (pts). ASH 2023;Abstract 832.
Perl AE et al. Outcomes in patients with FLT3-mutated relapsed/refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transplant Cell Ther 2023;29(4):265.e1-10. Abstract
Pratz KW et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol 2024;99(4):615-24. Abstract
Pratz KW et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: A phase IB study in patients with newly diagnosed AML. J Clin Oncol 2023;41(26):4236-46. Abstract
Ruhnke L et al. Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-ven) as salvage treatment for relapsed/refractory AML: Updated results of the phase-I/II SAL relax trial. ASH 2023;Abstract 160.
Stein AS et al. A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia. ASCO 2023;Abstract 7005.
Suo X et al. Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial. ASH 2023;Abstract 969.
Wei AH et al. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. Am J Hematol 2023;98(4):E84-7. Abstract
Yang Li et al. Selinexor in combination with venetoclax and azacitidine for newly diagnosed (nd) unfit acute myeloid leukemia (AML): A multicenter, open-label prospective study. ASH 2023;Abstract 55.